Rp

JCB and BNI Launch the BNI JCB Ultimate Card

Retrieved on: 
Thursday, September 21, 2023

(BNI) launched the latest credit card, BNI JCB Ultimate.

Key Points: 
  • (BNI) launched the latest credit card, BNI JCB Ultimate.
  • The BNI JCB Ultimate Card is targeted at the super-premium segment and focuses on dining transactions.
  • It will be extremely beneficial for Japanese premium dining enthusiasts and food lovers in general to frequently use the BNI JCB Ultimate Card for transactions.
  • The koi fish on the card symbolises good luck, success, and prosperity, which are BNI's hope for BNI JCB Ultimate cardholders.

CIMB Niaga and JCB launch JCB Contactless Credit Card in Indonesia

Retrieved on: 
Friday, September 3, 2021

JAKARTA & TOKYO, Sept 3, 2021 - (JCN Newswire) - PT Bank CIMB Niaga Tbk (CIMB Niaga) and PT JCB International Indonesia (JCB), as subsidiaries of JCB International Co Ltd., launched the CIMB Niaga JCB Contactless Credit Card in Jakarta, Friday, 3 September 2021.

Key Points: 
  • JAKARTA & TOKYO, Sept 3, 2021 - (JCN Newswire) - PT Bank CIMB Niaga Tbk (CIMB Niaga) and PT JCB International Indonesia (JCB), as subsidiaries of JCB International Co Ltd., launched the CIMB Niaga JCB Contactless Credit Card in Jakarta, Friday, 3 September 2021.
  • Meanwhile, President Director of PT JCB International Indonesia, Takumi Takahashi, said, "We are delighted that CIMB Niaga is the first bank in Indonesia to implement JCB Contactless through the launch of the CIMB Niaga JCB Contactless Credit Card.
  • The issuance of the CIMB Niaga JCB Contactless Credit Card is an initiative of CIMB Niaga and JCB to provide an easier, faster and simpler transaction experience.
  • CIMB Niaga JCB Contactless Credit Card customers can use the JCB Contactless feature at more than 100 thousand merchants in Indonesia.

Aldeyra Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, August 5, 2021

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today reported financial results for the quarter ended June 30, 2021 and recent corporate highlights.

Key Points: 
  • Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today reported financial results for the quarter ended June 30, 2021 and recent corporate highlights.
  • ET today to discuss second-quarter 2021 financial results and recent corporate highlights.
  • After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for 90 days.
  • Aldeyra Therapeutics is a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases.

Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Retinitis Pigmentosa

Retrieved on: 
Wednesday, August 4, 2021

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for ADX-2191 (methotrexate for intravitreal injection) for the treatment of retinitis pigmentosa (RP).

Key Points: 
  • Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for ADX-2191 (methotrexate for intravitreal injection) for the treatment of retinitis pigmentosa (RP).
  • Retinitis pigmentosa is a serious and incurable sight-threatening disease that represents a major unmet need in the field of ophthalmology, stated Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra.
  • "ADX-2191 has now received orphan designations for three distinct clinical indications, highlighting the broad platform potential of ADX-2191 to treat an array of rare retinal disorders.
  • Aldeyra Therapeutics is a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases.

Park City Group Expands Share Repurchase Program to $6 Million

Retrieved on: 
Tuesday, May 18, 2021

To date, the Company has repurchased approximately $3 million on the original $4 million repurchase authorization.\nUnder this new stock repurchase program, Park City may repurchase shares in accordance with all applicable securities laws and regulations.

Key Points: 
  • To date, the Company has repurchased approximately $3 million on the original $4 million repurchase authorization.\nUnder this new stock repurchase program, Park City may repurchase shares in accordance with all applicable securities laws and regulations.
  • Repurchases may be made at management's discretion from time to time on the open market or through privately negotiated transactions.
  • The repurchase program has been authorized for a period of two year and it may be suspended for periods or discontinued at any time.\nThe expansion of the repurchase program follows the Company\xe2\x80\x99s issuance of its Fiscal Third Quarter 2021 Earnings.
  • Park City Group may from time to time update these publicly announced projections, but it is not obligated to do so.

Park City Group Expands Share Repurchase Program to $6 Million

Retrieved on: 
Tuesday, May 18, 2021

To date, the Company has repurchased approximately $3 million on the original $4 million repurchase authorization.\nUnder this new stock repurchase program, Park City may repurchase shares in accordance with all applicable securities laws and regulations.

Key Points: 
  • To date, the Company has repurchased approximately $3 million on the original $4 million repurchase authorization.\nUnder this new stock repurchase program, Park City may repurchase shares in accordance with all applicable securities laws and regulations.
  • Repurchases may be made at management's discretion from time to time on the open market or through privately negotiated transactions.
  • The repurchase program has been authorized for a period of two year and it may be suspended for periods or discontinued at any time.\nThe expansion of the repurchase program follows the Company\xe2\x80\x99s issuance of its Fiscal Third Quarter 2021 Earnings.
  • Park City Group may from time to time update these publicly announced projections, but it is not obligated to do so.

2020 Insights into Retinitis Pigmentosa (RP) - Epidemiology Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 29, 2020

The "Retinitis Pigmentosa (RP) - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Retinitis Pigmentosa (RP) - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • According to the publisher's, the total diagnosed prevalent population of Retinitis Pigmentosa (RP) in the 7MM is 253,420 in 2017.
  • Out of the above-mentioned countries, which country would have the highest Incident population of Retinitis Pigmentosa during the forecast period (2020-2030)?
  • The Retinitis Pigmentosa epidemiology model is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies.

The Providence Service Corporation Announces Authorization of $75 Million Stock Repurchase Program

Retrieved on: 
Thursday, March 12, 2020

ATLANTA, March 12, 2020 (GLOBE NEWSWIRE) -- The Providence Service Corporation (Providence or the Company) (Nasdaq: PRSC), the countrys largest provider of non-emergency medical transportation (NEMT) programs and holder of a minority interest in Matrix Medical Network, today announced that its Board of Directors has approved a $75 million stock repurchase program (the New Stock Repurchase Program), effective as of March 12, 2020.

Key Points: 
  • ATLANTA, March 12, 2020 (GLOBE NEWSWIRE) -- The Providence Service Corporation (Providence or the Company) (Nasdaq: PRSC), the countrys largest provider of non-emergency medical transportation (NEMT) programs and holder of a minority interest in Matrix Medical Network, today announced that its Board of Directors has approved a $75 million stock repurchase program (the New Stock Repurchase Program), effective as of March 12, 2020.
  • Under the New Stock Repurchase Program, the Company may repurchase common stock, par value $0.001 per share with an aggregate value of up to $75 million through December 31, 2020.
  • The New Stock Repurchase Program does not obligate the Company to repurchase any particular amount of common stock, and it could be modified, suspended or discontinued at any time.
  • The Providence Service Corporation, through its fully-owned subsidiary LogistiCare Solutions, LLC and Circulation, Inc., is the nations largest manager of non-emergency medical transportation programs for state governments and managed care organizations.

FDA Post Approval Study Demonstrates Timely Identification of Right Heart Failure and Early Use of Impella RP Leads to Higher Survival

Retrieved on: 
Saturday, October 26, 2019

The protocol includes recommendations on patient selection and timely identification of right heart failure with subsequent implantation of Impella RP.

Key Points: 
  • The protocol includes recommendations on patient selection and timely identification of right heart failure with subsequent implantation of Impella RP.
  • These results, from the Impella RPs post-approval study, match the survival rate in the Impella RPs pre-approval study.
  • The FDA has confirmed the classification of Impella RP post-approval study patients into two categories: Recover Right protocol and salvage support.
  • Abiomed, Impella, Impella 2.5, Impella 5.0, Impella LD, Impella CP, Impella RP, and Impella Connect are registered trademarks of Abiomed, Inc., and are registered in the U.S. and certain foreign countries.

Impella RP Post-Approval Study Data Presented at ACC 2019

Retrieved on: 
Monday, March 18, 2019

The Recover Right protocol includes patients who met the inclusion and exclusion criteria of the Recover Right FDA PMA clinical trial for Impella RP.

Key Points: 
  • The Recover Right protocol includes patients who met the inclusion and exclusion criteria of the Recover Right FDA PMA clinical trial for Impella RP.
  • The Impella RP post-approval study data compares to a survival rate of 73% in the Impella RP PMA Study, 42% for surgically implanted CentriMag RVAS HDE study protocol, and 29% - 42% self-reported survival to transfer or discharge for adult cardiac ECMO patients1.
  • The Impella RP is the only device submitting post-approval study data on real-world patient outcomes, including salvage utilization.
  • The Abiomed logo, Abiomed, Impella, Impella 2.5, Impella 5.0, Impella LD, Impella CP, Impella RP, Impella Connect, and Recovering hearts.